Fresenius acquires Malteser hospitals in German state of North Rhine-Westphalia

Fresenius Helios is acquiring three hospitals and four connected medical care centers in the western German cities of Duisburg and Krefeld from the Malteser humanitarian aid group. The facilities have a total of 870 beds, and sales last year were about €160 million. Approximately 2,000 employees treat about 35,000 patients annually at the two locations.

The two Malteser Hospitals in Duisburg cover specialty areas including general surgery; internal medicine; ears, nose and throat medicine; oral and maxillofacial surgery, and geriatrics. Special expertise in hematological oncology is offered. At the Malteser Hospital in Krefeld, a comprehensive range of medical services includes oral and maxillofacial surgery, general surgery and internal medicine as the main specialty areas.

Dr. Francesco De Meo, who is responsible for Helios on the Fresenius Management Board, said: “We welcome the opportunity to acquire three additional Malteser hospitals just shortly after acquiring their hospital in Bonn. When they’re combined with our existing facilities, we will be able to offer the people of this region even better healthcare, tailored to their individual needs and with inpatient and outpatient care that go hand in hand. We are very much looking forward to working with our new colleagues.”

Fresenius Helios expects the acquisition, which is subject to approval by the German antitrust authorities, to close in the fourth quarter of this year. The three hospitals in Duisburg and Krefeld, along with the Malteser Hospital in Bonn, will be integrated into Helios Region West, where Helios already operates 18 acute care hospitals, a rehabilitation clinic and a number of medical care centers.

With approximately 18,000 employees, Helios treats some 300,000 inpatients annually in the region. The company is one of the largest healthcare employers in North Rhine-Westphalia, where Duisburg and Krefeld are situated, and the adjoining state of Lower Saxony.

The parties have agreed not to disclose the purchase price. The acquisition will be accretive to Group earnings starting in 2021.